Information Provided By:
Fly News Breaks for December 5, 2019
ACAD
Dec 5, 2019 | 07:32 EDT
Cowen analyst Ritu Baral noted Acadia presented its full Phase 3 HARMONY data which showed Pimavanserin had strong efficacy and safety and that it could be a major differentiator versus the current standard of care. The analyst believes it has blockbuster market potential. Baral reiterated her Outperform rating and $60 price target on Arcadia shares.
News For ACAD From the Last 2 Days
There are no results for your query ACAD